SemaCagri

SemaCagri – a combination of semaglutide and cagrilintide for laboratory tests

The category includes pre-dissolved containing pens blend of two peptides – semaglutide (GLP-1 analogue) and cagrilintide (long-acting amylin analogue). A class known in the pharmaceutical literature as CagriSema (Novo Nordisk), currently in phase III of the REDEFINE clinical program. In the One Peptides catalog it is present as Research Use Only reagent — not a medicinal product, not a dietary supplement. All items meet the standard HPLC ≥98%, have confirmation of identity by mass spectrometry (MS), a full certificate of analysis per batch and a maintained cold chain of 2-8°C. The full context of the incretin class (semaglutide, tirzepatide, retatrutide) describes GLP-1 peptide guide.

What is SemaCagri – a combination of two incretin-amylin peptides

SemaCagri is blend of two separate peptides administered in one formulation: semaglutide (an analogue of human GLP-1 with extended half-life, modified by C18 fatty acid conjugation and amino acid substitutions at position 8) and cagrilintide (long-acting amylin analog / pramlintide-like peptide with prolonged release kinetics). Each peptide interacts with a separate receptor and belongs to a different pharmacological class.

The pharmaceutical class referred to under the abbreviation “SemaCagri” is CagriSema — combination of semaglutide 2.4 mg + cagrilintide 2.4 mg developed by Novo Nordisk. Clinical program REDEFINE includes phase III in obesity (REDEFINE 1) and type 2 diabetes (REDEFINE 2). For now no regulatory authority – EMA, FDA or otherwise – has registered CagriSema as a medicinal product. Semaglutide monotherapy is registered (Ozempic, Wegovy, Rybelsus); Cagrilintide is not registered as a monotherapy.

Comparison table – two peptides, two receptors

The informal shorthand used for retatrutide in online searches is explained in a separate entry: what the informal term “reta” means.

Mechanism – two satiety pathways simultaneously

The mechanistic hypothesis behind the CagriSema combination is based on synergy of two distinct neuroanatomical circuits regulating satiety and glucose homeostasis.

GLP-1 axis (semaglutide): the GLP-1 receptor is present in pancreatic β-cells, the arcuate nucleus of the hypothalamus, the nucleus of the solitary tract (NTS) and in the peripheral endings of the vagus nerve. GLP-1R stimulation results in glucose-dependent insulin secretion, glucagon inhibition, slowing of gastric emptying, and a satiety signal in hypothalamic-stem circuits. A broader review of the incretin axis in article about GLP-1, GIP and glucagon.

Amylin axis (cagrilintide): the amylin receptor is a heterodimer of the calcitonin CTR receptor with a RAMP-modifying protein. The highest density of receptors occurs in area postrema — the structure of the brainstem outside the blood-brain barrier, whose task is to integrate humoral and visceral signals. Stimulation of the amylin receptor generates a satiety signal in a neuronal network other than GLP-1, additionally slows down gastric emptying and inhibits glucagon secretion.

The mechanistic synergy hypothesis assumes that simultaneous stimulation of two different neuroanatomical circuits (GLP-1R in the arcuate nucleus + amylin receptor in the area postrema) generates a stronger and more persistent appetite regulation signal than each axis individually. Clinical verification of this hypothesis is the subject of the REDEFINE program.

SemaCagri in the One Peptides catalog – RUO research reagent

It is present in this category Sema+Cagri PEN 2 mg + 2 mg — a pre-dissolved blend of both peptides in one injector, delivered ready for collection in laboratory conditions without the need for dissolution.

Formal status:

• Chemical reagent intended exclusively for laboratory tests (Research Use Only).
• Not a medicinal product — is not subject to registration as a drug in the EMA / FDA / URPL.
• Not a dietary supplement — is not subject to the EFSA framework.
• No indications for use in humans — intended use only in vitro / ex vivo / in research models according to the center’s protocol.

Standards: HPLC ≥98%, MS confirmation, COA per batch with separate data for semaglutide and cagrilintide, cold chain 2–8°C, batch traceability. A full description of the quality control procedure can be found in the section quality tests and certificates. Peptide calculator helps to calculate the concentration of ingredients in the pre-dissolved product.

SemaCagri vs CagriSema clinical vs GLP-1 drugs – fundamental difference

The three facilities with related names represent three distinct regulatory frameworks. Confusing them generates a real risk of interpretation – the table below organizes the distinction.

Frequently asked questions

How is SemaCagri different from just semaglutide (Ozempic)?

The substance itself: semaglutide in monotherapy (Ozempic, Wegovy, Rybelsus) acts exclusively through the GLP-1 receptor. SemaCagri is blend of two peptides — semaglutide and cagrilintide, a long-acting amylin analogue that stimulates a separate receptor (CTR + RAMP complex) in the area postrema of the brain stem. Mechanistically, the combination is engaging two different axes of satiety regulation simultaneously, while GLP-1 monotherapy – one. The formal status of both objects is also different: Ozempic is a prescription drug, SemaCagri in this category is an RUO reagent.

Is SemaCagri a medicine?

NO. Items in this category include Research Use Only reagents — not medicinal products, not dietary supplements. Pharmaceutical grade CagriSema (Novo Nordisk), referred to by the abbreviation “SemaCagri”, can be found in phase III clinical trials REDEFINE i program is not registered as a medicine at the EMA, FDA or any other regulatory body in the world. Registration as a registered medicine applies only to semaglutide as monotherapy (Ozempic, Wegovy, Rybelsus).

What is cagrilintide?

Cagrilintide is long-acting amylin analogue — pancreatic hormone co-secreted with insulin by β-cells. It was created as a modification of the structure of pramlintide (a registered short-acting amylin analogue) with an extended half-life enabling administration once a week. It acts through the amylin receptor – a heterodimer of the calcitonin CTR receptor and RAMP modifying protein. The highest density of receptors occurs in the area postrema of the brain stem. Cagrilintide as monotherapy there is no registration in any regulatory body; is developed by Novo Nordisk exclusively as a component of the CagriSema combination.

What is the status of the REDEFINE program?

REDEFINE is a global clinical research program phase III sponsored by Novo Nordisk, verifying the effectiveness and safety of the CagriSema combination. It includes two main arms: REDEFINE 1 (obesity – comparison with placebo and semaglutide monotherapy) and REDEFINE 2 (type 2 diabetes – comparison with semaglutide). Phase III is the last stage of clinical trials preceding the submission of a registration application – a positive result does not guarantee registration, and the dates of publication of the results and potential regulatory decision remain at the discretion of the sponsor and the registration authority. Current trial status data is available in the ClinicalTrials.gov and EU CTR registries.

Is SemaCagri on the WADA list?

Semaglutide (as a GLP-1 analogue) and cagrilintide (as an amylin analogue) are not included in the current WADA List of Prohibited Substances and Methods as substances prohibited in sport. However, athletes subject to anti-doping control should verify the current WADA list before each season, because the classification of substances is regulated annually. The CagriSema combination itself, as a pharmaceutical candidate, has not yet been mentioned separately.

Related categories and articles

• GLP-1 Peptide Guide
• Semaglutide – what we know from clinical trials
• GLP-1, GIP, glucagon – how incretins work
• Tirzepatide – dual GIP/GLP-1 agonist
• SEMA Category G – semaglutide monotherapy
• GLP-1+GIP category – tirzepatide
• One Peptides quality standards and certificates

All items in this category are chemical reagents intended only for laboratory tests (Research Use Only). They are not medicinal products, dietary supplements or foodstuffs. Pharmaceutical grade CagriSema (Novo Nordisk) to which these reagents refer can be found in phase III of REDEFINE clinical trials and is not registered with the EMA, FDA or any other regulatory body. Registration as a medicine only applies semaglutide monotherapy (Ozempic, Wegovy, Rybelsus on prescription). The content on this website is for informational and educational purposes and does not constitute medical advice, instructions for use, or encouragement for human administration.